The UK Competition Appeal Tribunal upholds an infringement decision for pay-for-delay pharmaceutical deals (GlaxoSmithKline)

CAT upholds infringement decision for pay for delay pharma deals* The Competition Appeal Tribunal has upheld the CMA decision that GlaxoSmithKline and some generic suppliers of the anti-depressant paroxetine broke competition law. The Competition Appeal Tribunal (Tribunal) has, however, imposed reduced fines of £27.1 million on the firms involved. Paroxetine is relied on by

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • United Kingdom’s Competition Authority - CMA (London)

Quotation

UK Competition Authority, The UK Competition Appeal Tribunal upholds an infringement decision for pay-for-delay pharmaceutical deals (GlaxoSmithKline), 10 May 2021, e-Competitions May 2021, Art. N° 100779

Visites 336

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues